International Symposium on Endovascular Therapy

EDAP Announces Third Quarter 2023 Financial Results

Retrieved on: 
Thursday, November 9, 2023
University of Zurich, AAGL, Hospital, EUR, USD, Overalls, Cleveland Clinic, International Symposium on Endovascular Therapy, Operating cost, EDT, Teaching hospital, University of Florida, Icahn School of Medicine at Mount Sinai, EDAP, League of European Research Universities, Prostate cancer, DACH, League, Marketing, Immunotherapy, University, Investment, Patient, TMS, Congress, Conference, Endo, Research, Growth, SEP, European Society of Gynaecological Oncology, Total, Poster, Lithotripsy, Mount Sinai Hospital, Randomized controlled trial, Pharmaceutical industry, Medical imaging, Film industry, Video game, Lithium, Medicine, Distribution, Urology

- Strong Q3 2023 U.S. Focal One® HIFU procedure growth of +150% year-over-year -

Key Points: 
  • - Strong Q3 2023 U.S. Focal One® HIFU procedure growth of +150% year-over-year -
    - Announces immunotherapy clinical research collaboration with Mount Sinai, Department of Urology -
    - Company to host conference call and webcast today, Thursday, November 9th at 8:30 am EDT -
    LYON, France, November 9, 2023 - EDAP TMS SA (Nasdaq: EDAP), the global leader in robotic energy-based therapies, reported today unaudited financial results for the third quarter ending September 30, 2023.
  • The decrease was driven by 1 Focal One system sold in the third quarter 2023 versus 3 systems sold in the third quarter of 2022.
  • Operating loss for the third quarter of 2023 was EUR 5.6 million (USD 6.0 million), compared to an operating loss of EUR 2.1 million (USD 2.2 million) in the third quarter of 2022.
  • A conference call and webcast to discuss the third quarter 2023 financial results will be hosted Ryan Rhodes, Chief Executive Officer, François Dietsch, Chief Financial Officer and Ken Mobeck, Chief Financial Officer of the U.S. subsidiary, today, Thursday, November 9th, 2023, at 8:30am EDT.

Calliditas Interim Report January - September 2023

Retrieved on: 
Tuesday, November 7, 2023
International Symposium on Endovascular Therapy, FDA, Operating cost, PDUFA, SEK, Nephrology, Magazine, ASN, NOX, USD, CMO, IgA nephropathy, Alport syndrome, Rare-earth element, Cryptocurrency, Pharmaceutical industry, Alport, EU, Lancet

Operating loss amounted to SEK 159.6 million and SEK 36.2 million for the three months ended September 30, 2023, and 2022, respectively.

Key Points: 
  • Operating loss amounted to SEK 159.6 million and SEK 36.2 million for the three months ended September 30, 2023, and 2022, respectively.
  • Significant Events in Q3 2023, in Summary
    On July 13 Calliditas announced supportive interim data from Phase 2 head and neck cancer trial with lead NOX inhibitor candidate, setanaxib.
  • Calliditas invites investors, analysts and press to a presentation of the Quarterly Report 2023 at 14:30 pm.
  • Calliditas' CEO Renee Aguiar-Lucander will present the report together with CFO Fredrik Johansson, CMO Richard Philipson and President North America Andrew Udell.

Calliditas Interim Report January - September 2023

Retrieved on: 
Tuesday, November 7, 2023
International Symposium on Endovascular Therapy, FDA, Operating cost, PDUFA, SEK, Nephrology, Magazine, ASN, NOX, USD, CMO, IgA nephropathy, Alport syndrome, Rare-earth element, Cryptocurrency, Pharmaceutical industry, Alport, EU, Lancet

Operating loss amounted to SEK 159.6 million and SEK 36.2 million for the three months ended September 30, 2023, and 2022, respectively.

Key Points: 
  • Operating loss amounted to SEK 159.6 million and SEK 36.2 million for the three months ended September 30, 2023, and 2022, respectively.
  • Significant Events in Q3 2023, in Summary
    On July 13 Calliditas announced supportive interim data from Phase 2 head and neck cancer trial with lead NOX inhibitor candidate, setanaxib.
  • Calliditas invites investors, analysts and press to a presentation of the Quarterly Report 2023 at 14:30 pm.
  • Calliditas' CEO Renee Aguiar-Lucander will present the report together with CFO Fredrik Johansson, CMO Richard Philipson and President North America Andrew Udell.

Prime Medicine Reports Third Quarter 2023 Financial Results and Provides Business Updates

Retrieved on: 
Friday, November 3, 2023
Gene editing, International Symposium on Endovascular Therapy, FDA, Research, Food, Rhodopsin, Human, Congress, Fragile X syndrome, G&A, Liver, CFTR, Chromosomal translocation, Regulation of tobacco by the U.S. Food and Drug Administration, Cell, Initial, R, Society, ASH, RHO, Tissue, Lung, Cystic fibrosis, Prime editing, Gene, Composition, Abstract, LNP, Eye, Safety, European Society of Clinical Microbiology and Infectious Diseases, Investment, CGD, Patient, Retina, NHP, Patent, D, Vaccine, Pharmaceutical industry, Fine chemical, Beef cattle, Video game, Cryptocurrency, IND

CAMBRIDGE, Mass., Nov. 03, 2023 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, today reported financial results and provided business updates for the third quarter ended September 30, 2023.

Key Points: 
  • 11,795,452 --
    CAMBRIDGE, Mass., Nov. 03, 2023 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, today reported financial results and provided business updates for the third quarter ended September 30, 2023.
  • Together, these encouraging results mark meaningful progress toward the clinic and support our strategy of simultaneously advancing multiple programs forward.
  • In August 2023, Prime Medicine received Rare Pediatric Drug designation (RPDD) from the U.S. Food and Drug Administration (FDA) for PM359.
  • Year-to-date, Prime Medicine continues to make significant progress, executing against key initiatives to drive its Prime Editing platform forward.

Prime Medicine Presents First In Vivo Proof-of-Concept Prime Editing Data Demonstrating Ability of Prime Editors to Treat Ophthalmological Diseases

Retrieved on: 
Tuesday, October 24, 2023
Well, International Symposium on Endovascular Therapy, AAV, Rhodopsin, RNA, Congress, Photoreceptor, PCR, Research, Retinal, RHO, Disease, Glial fibrillary acidic protein, Retina, GFAP, Eye, Paratriathlon, Patient, Gene expression, Vaccine

CAMBRIDGE, Mass., Oct. 24, 2023 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated, one-time curative genetic therapies, today reported new preclinical data demonstrating the ability of Prime Editors to efficiently and precisely correct the predominant mutations that cause rhodopsin associated autosomal dominant retinitis pigmentosa (RHO adRP). The data were presented today at the International Symposium on Retinal Degeneration 2023 Congress (RD2023) in Costa del Sol, Spain.

Key Points: 
  • The data were presented today at the International Symposium on Retinal Degeneration 2023 Congress (RD2023) in Costa del Sol, Spain.
  • “The data presented today are the first proof-of-concept data for Prime Editing’s application in treating ophthalmological indications, and highlight the ability of Prime’s novel, dual AAV delivery platform to efficiently deliver Prime Editors to the eye,” said Jeremy Duffield, M.D., Ph.D., Chief Scientific Officer of Prime Medicine.
  • In today’s presentation at RD2023, Prime Medicine shared findings from in vivo studies in humanized mice with its Prime Editors targeting these prevalent RHO mutations.
  • Efficient delivery of Prime Editors by dual AAV to human (retinal explants) and murine (in vivo) photoreceptors.

Travere Therapeutics to Present Abstracts at the 17th International Symposium on IgA Nephropathy (IIGANN 2023)

Retrieved on: 
Tuesday, September 26, 2023
Kidney failure, Jay Traver, SPARTAN, IgA nephropathy, Immunoglobulin A, Proteinuria, International Symposium on Endovascular Therapy, Patient, SAN, Radar, Therapy, Safety, Pharmaceutical industry

SAN DIEGO, Sept. 26, 2023 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that the Company and its collaborators will present preliminary findings from the SPARTAN Study evaluating the potential effect of FILSPARI® (sparsentan) as a first-line therapy in patients with newly diagnosed IgA nephropathy (IgAN) in a late-breaking trial session at the 17th International Symposium on IgA Nephropathy (IIGANN2023) in Ryogoku, Tokyo, September 28-30, 2023.

Key Points: 
  • SAN DIEGO, Sept. 26, 2023 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that the Company and its collaborators will present preliminary findings from the SPARTAN Study evaluating the potential effect of FILSPARI® (sparsentan) as a first-line therapy in patients with newly diagnosed IgA nephropathy (IgAN) in a late-breaking trial session at the 17th International Symposium on IgA Nephropathy (IIGANN2023) in Ryogoku, Tokyo, September 28-30, 2023.
  • The Company will also present preclinical data supporting the nephroprotective mechanism of action of sparsentan, a dual endothelin angiotensin receptor antagonist, and an analysis of the UK National Registry of Rare Renal Diseases (RaDaR) which demonstrated that patients with IgAN traditionally considered ‘low-risk’, with proteinuria less than one gram per day, had high rates of kidney failure.
  • “Patients with IgA nephropathy need both early and effective treatment options capable of significant and sustained reduction of proteinuria to preserve kidney function,” said Jula Inrig, M.D., chief medical officer of Travere Therapeutics.
  • “We’re pleased to be presenting 24-week data on proteinuria reduction, blood pressure control, and safety from the ongoing SPARTAN Study evaluating the effect of sparsentan as a first-line treatment option in patients with newly diagnosed IgAN.”
    Sparsentan Treatment of Incident Patients With IgA Nephropathy as First-line Therapy: Interim Findings From the SPARTAN Trial

Perspective Therapeutics Reports Second Quarter Fiscal 2023 Results and Recent Business Highlights

Retrieved on: 
Friday, August 11, 2023
GMP, Mayo Clinic, GE HealthCare, Safety, Glomus tumor, Doctor of Philosophy, Audit committee, Medicare, Journal, CATX, Patient, Investment, RLS, R, ED, NYSE, Brain, Prostate cancer, Centers for Medicare & Medicaid Services, University, Viewpoint, Fortis Healthcare, Research, Nuclear medicine, Rated R, Radiosurgery, Radiation, Knowledge, Growth, FDA, Bander, SPECT, GT, Roche, Isotopes of thorium, USP, 1991 World Sportscar Championship, Documentation, International Symposium on Endovascular Therapy, Neurosurgery, Therapy, Joint Commission, Isotopes of caesium, SNMMI, MC1R, Molecular imaging, PET, University of Iowa, CDMO, Melanoma, Medical imaging, Pharmaceutical industry, Management, Health insurance, MD, Brachytherapy, Operation

RICHLAND, Wash. and CORALVILLE, Iowa, Aug. 11, 2023 (GLOBE NEWSWIRE) -- Perspective, Therapeutics, Inc. (“Perspective” or “the Company”) (NYSE AMERICAN: CATX), a precision oncology company developing alpha-particle therapies and complementary diagnostic imaging agents and an innovator in seed brachytherapy powering expanding treatment options for multiple cancers, reports second quarter financial results for the period ended June 30, 2023 and recent business highlights.

Key Points: 
  • RICHLAND, Wash. and CORALVILLE, Iowa, Aug. 11, 2023 (GLOBE NEWSWIRE) -- Perspective, Therapeutics, Inc. (“Perspective” or “the Company”) (NYSE AMERICAN: CATX), a precision oncology company developing alpha-particle therapies and complementary diagnostic imaging agents and an innovator in seed brachytherapy powering expanding treatment options for multiple cancers, reports second quarter financial results for the period ended June 30, 2023 and recent business highlights.
  • With a strong team in place, we’re focused on securing new business and re-gaining old business.
  • For the first half of fiscal 2023 ended June 30, 2023, revenue decreased 23% to $4.2 million versus $5.4 million in the prior year comparable period.
  • Prostate brachytherapy represented 42% of total revenue for the first six months of fiscal 2023 compared to 73% for the first six months of fiscal 2022.

2023 International Symposium on Human Identification (ISHI) Keynote Offers Message of Resilience for Forensics Professionals

Retrieved on: 
Tuesday, July 25, 2023
Medical Supplies, Law Enforcement, Emergency Services, Public Policy, Government, Biotechnology, Other Health, Health, General Health, Other Science, Science, Law enforcement, Burnout, CODIS, DNA, CO, Promega, Hope, International Symposium on Endovascular Therapy, Multimedia, Colorado Convention Center, Fatigue, Management

The 34th International Symposium on Human Identification (ISHI) will welcome more than 900 forensic DNA experts and law enforcement professionals from around the world September 18-21 in Denver.

Key Points: 
  • The 34th International Symposium on Human Identification (ISHI) will welcome more than 900 forensic DNA experts and law enforcement professionals from around the world September 18-21 in Denver.
  • Keynote speaker Allison Massari, an award-winning motivational speaker, will deliver a message on resilience and responding to difficult circumstances.
  • View the full release here: https://www.businesswire.com/news/home/20230720723554/en/
    The 34th International Symposium on Human Identification will take place September 18-21 in Denver.
  • Promega Corporation, a developer and manufacturer of products for DNA-based human identification, has sponsored ISHI since its inception.

Susan M. Love, MD, MBA, Chief Visionary Officer and "Founding Mother" of Breast Cancer Advocacy and Research Dies

Retrieved on: 
Monday, July 3, 2023
President Clinton, Volunteering, Love, Executive, Surgeon, Fordham University, University, Army, Brigham and Women's Faulkner Hospital, Parent, State university system, Radiology, National Breast Cancer Coalition, Anderson School, Marriage, Woman, MBA, Research, History, Alpha Omega Alpha, Young Survival Coalition, Movement, HRT, NBCC, SUNY Downstate Medical Center, Beth Israel Hospital, International Symposium on Endovascular Therapy, MD, Breast cancer, The New York Times, Patient, Notre Dame, Revlon, Breast, Supreme court, School Sisters of Notre Dame, LOS, AI, Oncology, UCLA, State University of New York Upstate Medical University, Leukemia, Mammography, NIH, Hormone replacement therapy, Birth control, Medical device

LOS ANGELES, July 3, 2023 /PRNewswire/ -- Susan M. Love, MD, MBA, who led Dr. Susan Love Foundation for Breast Cancer Research since 1995, steering the Foundation through its innovative and life-changing research and advocacy programs, has died. She was 75.

Key Points: 
  • She was an early advocate of cancer surgery that conserves as much breast tissue as possible.
  • A founder of the breast cancer advocacy movement in the early 1990's, she helped organize the National Breast Cancer Coalition (NBCC) .
  • As Founder and Chief Visionary Officer of the Dr. Susan Love Foundation for Breast Cancer Research, Dr. Love built and oversaw an active research program centered on the cause and prevention of breast cancer.
  • The Love Research Army, which she launched in 2008, creatively accelerated cancer research by partnering volunteers and scientists for clinical trials and cancer research.

aTyr Pharma to Highlight Advancements in tRNA Synthetase Biology Research at the 13th International Symposium of Aminoacyl-tRNA Synthetases (AARS 2023)

Retrieved on: 
Tuesday, June 6, 2023
AARS, Therapy, Inflammation, Small RNA, ATyr Pharma, Neuropilin, Research, Sarcoidosis, FC, IUBMB, Biomarker, Biochemistry, Molecular biology, Protein, Glossary of biology, International Union of Biochemistry and Molecular Biology, International Symposium on Endovascular Therapy, Patient, SAN, HARS, Safety, Vaccine, Pharmaceutical industry, Conference

SAN DIEGO, June 06, 2023 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a clinical stage biotherapeutics company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced multiple presentations at the International Union of Biochemistry and Molecular Biology’s 13th International Symposium of Aminoacyl-tRNA Synthetases (AARS 2023), which is scheduled to take place June 4 – 9 in Ontario, Canada.

Key Points: 
  • Conference hosted by the International Union of Biochemistry and Molecular Biology (IUBMB) to feature leading research in tRNA synthetase biology.
  • Presentations showcase company’s progress in generating new therapeutics from tRNA synthetase platform.
  • “As a leader in the field of tRNA biology, we look forward to highlighting some of the recent findings from our platform at AARS 2023,” said Leslie A. Nangle, Ph.D., Vice President, Research at aTyr.
  • aTyr is focused on elucidating novel pathways mediated through extracellular tRNA synthetases and creating new biologics to modulate these pathways by developing protein therapies based on extracellular tRNA synthetase fragments.